Rx for Revenue: Welcure Bags ₹856M in Fresh Pharma Orders

Welcure Drugs & Pharmaceuticals Ltd has reported new orders of ₹856 million, a milestone in its current expansion and turnaround strategy. The group, boasting its diversified portfolio of pharmaceutical formulations, reported this as it makes aggressive inroads into domestic as well as international markets.

 

What the Order Implies for Welcure

Strategic Context

About Welcure Drugs & Pharmaceuticals

Welcure, which was incorporated in 1992 and listed on Bombay Stock Exchange, deals with more than 100 pharmaceutical products in tablet, capsule, and dry syrup presentations. Its major products are Brucure, Diclo-plus, and Nimesulide, etc.

 

Sources: Welcure Drugs & Pharmaceuticals, Zerodha, Screener